Refael Meyuchas

Erdheim-Chester disease (ECD) is a rare clonal histiocytic neoplasm characterized by tissue infiltration of CD68⁺/CD1a⁻ histiocytes and systemic inflammation [1]. While MAPK pathway mutations are well recognized [2], epigenetic mechanisms underlying both the neoplastic and inflammatory components of ECD are only beginning to be elucidated [3,4,5]. The recent publication by Cerván-Martín et al.

Histiocytic neoplasms are a rare group of diseases with significant morbidity due to histiocytic infiltration to critical organ systems, impeding their normal functions. Diagnosis is based on the identification of CD68+ histiocyte infiltration within tissues, demonstrating varied expression of dendritic and monocytic lineage cells depending on the type of histiocytosis [1, 2].